A Cancer Discovery Born From Ancient Medicine.Built by an Entrepreneur Who Already Created a $240M Company.⁵

Accredited investors only. This offering relies on Rule 506(c) of Regulation D, which means your accredited status has to be verified before you can subscribe. You qualify if you earn over $200,000 a year ($300,000 with a spouse), hold a net worth above $1M excluding your home, or hold certain securities licenses.

A separate Regulation A+ round is planned for all investors, accredited or not, at a lower minimum. That round is not yet qualified by the SEC, so no money can be accepted for it yet. Non-accredited investors can reserve a place now at no cost and with no obligation, and we will notify you when it opens and confirm its final terms.

The PPM sets the minimum at 6,150 units, or $25,092, and the Company may accept less at its discretion.

Units in NextGen Scientific, LLC. NextGen invests those proceeds into Ionics Life Sciences Limited, the parent company that owns both operating businesses: Genzada, the drug program, and Hyatt Life Sciences, the Afaya supplement brand. Your units give you an indirect stake in the whole platform, drugs and consumer health together. The Private Placement Memorandum is the controlling document and describes the structure in full. Read it, including the risk factors, before you invest.

Start with "Invest Now," verify your accredited status, review the offering documents, and complete your subscription through Texture Capital. Prefer to talk first? Book a call and the team will walk you through it.

Not easily. These units are restricted and illiquid, with no public market. You should expect to hold for an indefinite period and treat this as a long-term, high-risk position.

December 31, 2026, unless the maximum is reached first or the Company extends it. The raise is conducted on a best-efforts basis with no minimum, so the Company keeps what it raises.

High. This is a speculative investment in early-stage science, and you could lose your entire contribution. Clinical programs can fail, timelines can slip, and the units may never become liquid. Review the risk factors in the PPM and speak with your own advisors.

GZ17-6.02 completed a Phase 1 trial in patients with advanced solid tumors and lymphoma who had failed prior treatments. Results, published in Annals of Oncology in 2021, showed biological activity across eight tumor types with no Grade 4 or 5 adverse events, and a reported 23.5% clinical benefit rate. The compound has since moved into an investigator-initiated Phase 1B trial at Virginia Commonwealth University in advanced prostate cancer. GZ17-6.02 is investigational, is not FDA-approved, and early results do not guarantee later outcomes.

Once you complete your investment, the funds go to an escrow account held by an independent agent until NextGen accepts the subscription. After acceptance and the required regulatory steps, the money moves to NextGen, which invests it into Ionics Life Sciences Limited, and your units are issued.

ACH, wire transfer, debit card, credit card, or check, all through the secure online platform. Investments are accepted from accredited investors only.

Yes. NextGen Scientific accepts investments from self-directed IRAs (SDIRAs) and certain self-directed 401(k) plans. The investment is made by your retirement account, not by you personally, with shares held by your custodian on your behalf.

Investing through a retirement account offers several practical advantages:

• Tax treatment that matches the investment timeline. Private placements like this one are typically held for several years before any liquidity event. Holding shares inside a Traditional IRA or 401(k) lets returns compound on a tax-deferred basis until you take distributions in retirement. A Roth IRA or Roth 401(k) provides tax-free growth on qualified withdrawals.
• Diversification beyond public markets. Most retirement accounts are concentrated in publicly traded stocks, bonds, and mutual funds. A private placement gives your retirement portfolio exposure to early-stage healthcare development that does not move in lockstep with public market cycles.
• A long-term horizon that aligns with private investing. Retirement accounts are designed to be held for years or decades. A pre-IPO private placement is also illiquid for an extended period. The two timelines fit together naturally.

To invest through a retirement account, you will need a self-directed IRA custodian (such as Equity Trust, Alto, or STRATA Trust Company). Texture Capital, our broker-dealer, works with custodians familiar with this process and can help guide you through the steps. Speak with your tax advisor about whether this approach fits your retirement plan and overall financial circumstances.

No. GZ17-6.02 is an investigational compound and has not been approved by the FDA.

Yes. A Phase 1 study was completed and published.

Potential paths include partnerships, licensing, acquisition, or continued development.

The Reg A+ offering is intended for all investors after SEC qualification. Accredited investors may participate in the current Reg D offering.